Trial Profile
A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms IMpassion130
- Sponsors Chugai Pharmaceutical; Genentech; Roche
- 09 Nov 2022 Cost effectiveness analysis from KEYNOTE-355 and IMPASSION-130 presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 07 Jun 2022 Results evaluating biological changes in the TME induced by atezolizumab and nPearly on treatment (OT) and at the time of progressive disease (PD) in IMpassion130 presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results of post-hoc comparative analysis assessing Impact of steroid premedication on atezolizumab (atezo)-induced immune cell activation from peripheral blood mononuclear cells collected from patients from IMpassion130 and IMpassion131 studies, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.